Efficacy by genotype in recent randomized trials of standard treatments with pegylated interferon-α (PegIFNα) plus ribavirin and the novel regimens based on direct-acting antiviral agents
*Detailed references in Liang and Ghany58 and in the 2014 guidelines of the European Association for the Study of the Liver (EASL).41
†Patients with cirrhosis were included in the trial.
Sign In or Create an Account